Effect of Enhanced Primary Care for People with Serious Mental Illness on Service Use and Screening

Bridging the Gaps: Taking Care of the Whole Person

“…This regimen is both tolerable and has good long-term outcomes (the most recent update shows a 53% progression-free survival [PFS] rate at 5 years). Unfortunately, despite the PFS advantage, many practitioners in the community have not yet adopted this as first-line therapy and are most commonly utilizing RVd-lite (lenalidomide, bortezomib [Velcade], and dexamethasone), 6 a regimen with a less favorable administration schedule, increased risk of toxicity (eg, peripheral neuropathy), and shorter PFS.…”

“…Table 4 summarizes the adverse reactions in RET Fusion-Positive NSCLC Patients in ARROW. 1 Fatigue includes fatigue, asthenia 2 Edema includes edema peripheral, face edema, periorbital edema, eyelid edema, edema generalized, swelling 3 Diarrhea includes diarrhea, colitis, enteritis 4 Musculoskeletal pain includes back pain, myalgia, arthralgia, pain in extremity, musculoskeletal pain, neck pain, musculoskeletal chest pain, bone pain, musculoskeletal stiffness, arthritis, spinal pain 5 Hypertension includes hypertension, blood pressure increased 6 Cough includes cough, productive cough, upper-airway cough syndrome 7 Pneumonia includes pneumonia, atypical pneumonia, lung infection, pneumocystis jirovecii pneumonia, pneumonia bacterial, pneumonia cytomegaloviral, pneumonia haemophilus, pneumonia influenza, pneumonia streptococcal *Only includes a Grade 3 adverse reaction Table 5 summarizes the laboratory abnormalities in ARROW.…”

“…Oxaliplatin is a third-generation platinum alkylating agent that has demonstrated efficacy against a variety of tumor types, both in adjuvant and metastatic regimens. [1][2][3][4][5][6] Oxaliplatin is widely used in treatment of gastrointestinal (GI) cancers, including the FOLF-OX regimen (folinic acid, fluorouracil [5FU], and oxaliplatin) for colorectal cancer and gastroesophageal cancer and the FOLFIRINOX regimen (leucovorin calcium, 5FU, irinotecan hydrochloride, and oxaliplatin) for pancreatic cancer. Unfortunately, oxaliplatin use is limited by the development of drug-related neuropathy and drug hypersensitivity reaction (HSR).…”

“…5 "Double-hit" biallelic inactivation of TP53 (eg, del[17p] in one allele plus mutation in the other allele) appears to be associated with the highest risk, although a recent publication demonstrated that del(17p) by itself is also associated with poor outcomes. 6,7 A number of gene signatures associated with standard-or high-risk disease have been reported over the years, and while the different panels have been demonstrated to identify different risk groups, these panels generally do not share any overlapping genes across the signatures. 8 Thus, consensus has not been reached in the field regarding the optimal gene expression profiling (GEP) panel to utilize, and therefore this testing is not considered SOC.…”

Applying Care Coordination Principles to Reduce Cardiovascular Disease Risk Factors in People With Serious Mental Illness: A Case Study Approach

“…Future program implementation may wish to start in settings that care for high number of individuals with SMI. Enhanced primary care models and BHHs are natural settings because they focus on populations with SMI, and in the case for BHHs, have an existing funding through the Medicaid waiver program ( 27 , 51 ). Models that integrate somatic and behavioral health across acute and outpatient settings may also be of interest given their focus on individuals with SMI to maintain overall health after hospital admission ( 52 ).…”